WO1999033796A1 - Derives de 5-arylpyrrole - Google Patents
Derives de 5-arylpyrrole Download PDFInfo
- Publication number
- WO1999033796A1 WO1999033796A1 PCT/JP1998/005972 JP9805972W WO9933796A1 WO 1999033796 A1 WO1999033796 A1 WO 1999033796A1 JP 9805972 W JP9805972 W JP 9805972W WO 9933796 A1 WO9933796 A1 WO 9933796A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- compound
- salt
- lower alkyl
- methyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/333—Radicals substituted by oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
Definitions
- the present invention relates to 5-arylpyrrolyl derivatives such as 4,5-diarylpyrrole derivatives having an anti-inflammatory action, antipyretic action, analgesic action, anti-rheumatic action and production of cell growth inhibition, and anti-inflammatory drugs containing the compound as an active ingredient. It relates to an inflammatory agent and an antitumor agent.
- Nonsteroidal anti-inflammatory drugs work by inhibiting cyclooxygenase (COX), and cyclooxygenases include cyclooxygenase.
- COX-1 is also present in the gastrointestinal tract, etc., and its inhibition causes side effects such as gastrointestinal tract disorders.
- COX-2 appears only when inflammation occurs, a compound that selectively inhibits COX-2 is expected as a drug with few side effects [Mebio, Vol. 11, No. 10, p. (1994)].
- C0X-2 selective inhibitors are expected as antitumor agents [CANCER RESEARCH. 55, 3785 (1995 Year) ;].
- the selective inhibitory activity of OX-2 is, for example, higher than that of compounds in which the 2- and 3-positions of 4,5-diarylpyrrol are hydrogen than those in which a substituent of the electron-absorbing I group is introduced. Activity is rather reduced. Also, no electron-donating group is found as a substituent at the 2- or 3-position. Further, there is no description about the cell growth inhibitory effect.
- An object of the present invention is to provide an anti-inflammatory agent and an antitumor agent which selectively inhibit COX-2 and have no side effects such as gastric damage.
- the present invention provides a compound represented by the general formula (I):
- R 1 represents a hydrogen atom or a lower alkyl group.
- R 2 represents a lower alkynole group, (CH 2 ) mCOOH (nl is 1, 2 or 3).
- R 3 is a hydrogen atom, a halogen atom, a lower alkynole group, a hydroxymethyl group, a carboxyl group (CO 0H), a lower alkoxycarbonyl group, a lower alkoxymethynole group, a carbamoyl group (CONH 2 ), a mono-lower alkyl It represents a levamoinole group or a di-lower alkylcarba'moyl group.
- ⁇ Is lower alkyl, halogen, lower alkoxy, lower alkylthio, nitro, alkanoyl, cyano, amino, mono-lower alkylamino, di-lower alkylamino, alkanoylamino and A phenyl group, a bicyclic heteroaryl group or a phenylethynyl group which may be substituted with a functional group selected from the group consisting of alkanoinoleoxy groups; and a lower alkynyl group.
- R 5 represents a lower alkyl group, an amino group, a mono-lower alkylamino group or a di-lower alkylamino group.
- an anti-inflammatory and anti-inflammatory agent comprising the compound as an active ingredient. It is a tumor agent.
- lower alkyl group examples include linear or branched alkyl groups having 1 to 6 carbon atoms such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, pentyl, and hexyl. Is mentioned.
- halogen atom examples include a chlorine atom, a bromine atom, a fluorine atom, and an iodine atom.
- Lower alkoxycarbonyl groups include linear groups such as methoxycarbonyl, ethoxycarbonyl, n-propoxycarbonyl, i-propoxycarbonyl, n-butoxycarbonyl, i-butoxycarbonyl, sec-butoxycarbonyl, and t-butoxycarbonyl.
- a branched alkoxyl group having 1 to 6 carbon atoms may be used.
- Examples of the lower alkoxy group include methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, i-butoxy, sec-butoxy, t-butoxy and the like.
- An alkoxy group is methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, i-butoxy, sec-butoxy, t-butoxy and the like.
- Examples of the lower alkoxymethyl group include a lower alkoxymethyl group having 2 to 5 carbon atoms such as methoxymethyl, ethoxymethyl, isopropoxymethyl, and t-butoxymethyl.
- Mono-lower alkyl moieties such as methylcarba moyl, ethyl campolepa, moyl, n-propylcasoleva moyl, i-propyl moieve, and n-butylcanolevamoinole have 2 to 5 carbon atoms. And a carbamoyl group.
- di-lower alkyl rubamoinole group examples include dimethylcasolebamoyl, getyl carbamoyl, di (n-propyl) rububamoyl, di (i-propyl) rubamoinole, di (n-butyl) carbamoyl, etc. And 9 dialkyl canolebamoyl groups.
- lower alkylthio group examples include straight-chain or branched C1-C6 groups such as methylthio, ethylthio, n-propylthio, isopropylthio, n-butylthio, isobutylthio, sec-butylthio, t-butylthio, pentylthio, and hexylthio.
- Alkylthio group strength such as methylthio, ethylthio, n-propylthio, isopropylthio, n-butylthio, isobutylthio, sec-butylthio, t-butylthio, pentylthio, and hexylthio.
- Lower alkanoyl groups include formyl, acetyl, propionyl, butyryl And C 1 -C 4 alkyl groups.
- Examples of the mono-lower alkylamino group include methylamino, ethylamino, n-aminopyramino, isopropylamino, n-butylamino, isoptylamino, sec-butylamino, t-butylamino, pentylamino, hexinoleamino and the like.
- a linear or branched monoalkylamino group having 1 to 6 carbon atoms is exemplified.
- di-lower alkylamino group examples include linear or branched carbons such as dimethylamino, getylamino, di-n-propylamino, diisopropylamino, di-n-butylamino, diisobutylamino, di-sec-butylamino, and di-tert-butylamino.
- An amino group di-substituted with an alkyl group of the formulas 1 to 4 is exemplified.
- alkanoylamino group examples include C1-C4 alkynylamino groups such as formylamino, acetylamino, propionylamino, and butyrylamino.
- alkanoyloxy group examples include alkynyloxy groups having 2 to 4 carbon atoms, such as acetyloxy, propionyloxy, and butyryloxy.
- the position of the substituent is 2-position, 3-position or 4-position, preferably 3-position or 4-position, more preferably 4-position. is there.
- the position of the substituent is 2-3, 2-4, 2-5, 3-5 or 3-4, preferably 2-4 or 3-4.
- trisubstitution it is preferably at the 2,3,4 or 3,4,5 position.
- Preferred substituents include lower alkyl, lower alkoxy, halogen atoms, amino, mono- or di-lower alkylamino and lower alkylthio groups.
- the bicyclic heteroaryl group which may be substituted with the functional group is preferably 6-indolyl, 6-N-methylindolyl, 5-indolyl, 5-N-methylindolyl, 5- (2,3-Dihydrobenzofuranyl), 6- (2,3-Dihydrobenzofuranyl), 4- (3,4-methylenedioxyphenyl), 3-
- a bicyclic heteroaryl group is a 5- or 6-membered ring in which one ring is a benzene ring and the other is one or two heteroatoms (N, 0 or S) Group.
- substituent of the bicyclic heteroaryl group include the above functional groups, that is, a lower alkyl group and a halogen atom.
- a lower alkoxy group, a lower alkylthio group, a nitro group, an alkanol group, a cyano group, an amino group, a mono-lower alkylamino group, a di-lower alkylamino group, a lucanoylamino group and an alkanoyloxy group Preferably, a lower alkyl, a halogen atom, a hydroxyl group, a lower alkoxy, an amino, a mono- or di-lower alkylamino, a lower alkylthio, and especially a methinole group are exemplified.
- Examples of the substituent of the phenylethynyl group include the above functional groups, that is, a lower alkyl group, a halogen atom, a lower alkoxy group, a lower alkylthio group, a nitro group, an alkanol group, a cyano group, an amino group, a mono-lower alkylamino group, and a di-lower group.
- Examples thereof include an alkylamino group, an alkanoylamino group and an alkanoyloxy group, preferably a lower alkyl, a halogen atom, an alkoxy, an amino, a mono or a di-lower alkylamino, a lower alkylthio, and particularly a methinole group. .
- Examples of the lower alkynyl group include an alkynyl group having 2 to 6 carbon atoms such as an ethynyl group, a propynyl group, a butynyl group, a pentynyl group, and a hexynyl group.
- substituent of the phenylethynyl group include the above-described functional groups, and preferably include lower alkyl, lower alkoxy, a halogen atom, amino, mono- or di-lower alkylamino, and lower alkylthio.
- R 1 is a hydrogen atom, methynole or ethyl, more preferably a hydrogen atom or methyl, particularly preferably a hydrogen atom.
- Preferred R 2 is a lower alkyl group, especially a methyl group.
- Desirable R 3 is a 7-atom atom.
- R 4 is phenyl, 6-indolyl, 6-methyl-indolyl, 5-vinyl-, 5-N-methyl-indolyl, 5-(2,3- Dihydrobenzofuranyl), 6- (2,3-dihydrobenzofuranyl), 4- (3,4-methylenedioxyphenyl), 3- (3,4-methylenedioxyphenyl), phenylinoethynyl, Ethynyl and propynyl.
- R 4 is lower alkyl, lower alkoxy, halogen atom, amino group, mono- or di-lower alkylamino, phenyl group mono- or di-substituted with lower alkylthio, 6-N-methylindolyl, 5-N- Methyl indolyl, 5- (2,3-dihydrobenzofuranyl), 6- (2,3-dihydrobenzofuranyl) Or a phenylethynyl group.
- R 5 is methyl, NH 2 or NHMe, more preferably methyl or NH 2, are properly especially preferred is methyl.
- the compound of the general formula (I) of the present invention can be obtained, for example, according to the following reaction scheme 1>.
- R 1 represents a hydrogen atom or a lower alkyl group.
- R 2 represents a lower alkyl group, (CH 2 ) "COOH (nl is 1, 2 or 3).
- R 3 represents a hydrogen atom, a halogen atom, a lower alkyl group, a hydroxymethyl group, a carboxyl group (CO OH), a lower alkoxycarbonyl group, a lower alkoxymethynole group, a carbamoyl group (CONH 2 ), a mono lower alkyl canolebamoyl group or a di-lower alkyl carpa'moyl group.
- R 4 is a lower alkyl group, a halogen atom, a lower alkoxy group, a lower alkylthio group, a nitro group, an alkanoyl group, a cyano group, an amino group, a mono-lower alkylamino group, a di-lower alkylamino group, an alkanoylamino group A phenyl group, a bicyclic heteroaryl group or a phenylethynyl group which may be substituted with a functional group selected from the group consisting of alkanoyloxy group and alkanoyloxy group; or a lower alkynyl group.
- R 5 represents a lower alkyl group.
- Re represents a hydrogen atom or a lower alkyl group
- Z represents a halogen atom
- examples of the acid catalyst include aluminum chloride.
- This reaction is generally performed in a solvent, and examples of the solvent include dichloromethane, chloroform, carbon disulfide, nitrobenzene, and cyclobenzene.
- bromine compound (4) can be obtained by adding 1 equivalent of bromine to the compound (3) and reacting the mixture at a temperature of about ice-cooling to room temperature for 1 to 24 hours.
- This reaction can be carried out without solvent or by appropriately selecting a solvent such as dioxane, tetrahydrofuran, geethylether, n-hexane, cyclohexane, dichloromethane, chlorophonolem and the like.
- a solvent such as dioxane, tetrahydrofuran, geethylether, n-hexane, cyclohexane, dichloromethane, chlorophonolem and the like.
- Bases used in this reaction include lithium metal hydroxides such as lithium hydroxide, potassium hydroxide, and sodium hydroxide, sodium metal carbonates such as sodium carbonate and carbon dioxide, sodium hydrogen carbonate, and hydrogen carbonate.
- Alkali metal hydrogencarbonates such as sodium hydride, sodium hydride, alkaline metal hydrides such as hydrogen hydride, inorganic bases such as metal sodium, sodium amide or triethylamine, triethylamine
- Organic bases such as n-butylamine, pyridine and N, N-dimethylaminopyridine.
- the salt in this reaction includes a sodium salt, a potassium salt and the like.
- This reaction is carried out without solvent or dioxane, tetrahydrofuran, getyl ether, n-hexane, cyclohexane, dichloromethane, chloroform, ethyl acetate, benzene, xylene, acetone, acetonitrile, N, N-dimethylformamide, It can be carried out by appropriately selecting a solvent such as dimethylszolefoxide and water. (Process D)
- the oxidation may be carried out by a method of converting an alkylthio group to an alkylsulfonyl group, for example, a method using an oxidizing agent such as aqueous hydrogen peroxide or 3-chloroperbenzoic acid.
- an oxidizing agent such as aqueous hydrogen peroxide or 3-chloroperbenzoic acid.
- the solvent used in this reaction may be appropriately selected depending on the oxidation method, and generally, dioxane, tetrahydrofuran, dimethyl ether, n-hexane, cyclohexane, dichloromethane, chloroform, benzene, xylene And so on.
- the sulfone compound (7) is added in an amount of 1 equivalent to an excess amount of the amino compound or ammonium salt represented by 1 volume 2 and room temperature to 100 ° C.
- the compound of the formula (IA) can be obtained by reacting at a temperature of about C to a reflux temperature of the solvent for 1 to 24 hours.
- Amino compounds and ammonium salts in this reaction include methylamine hydrochloride Salt, ethylamine, n-propylamine, isopropylamine, n-butylamine, S-butylamine, t-butylamine, ammonium carbonate, ammonium acetate and the like.
- This reaction can be carried out without solvent or by appropriately selecting a solvent such as dioxane, tetrahydrofuran, dimethyl ether, n-hexane, cyclohexane, dichloromethane, chloroform, benzene, or xylene.
- a solvent such as dioxane, tetrahydrofuran, dimethyl ether, n-hexane, cyclohexane, dichloromethane, chloroform, benzene, or xylene.
- a carboxylic acid compound in which R 3 is a carboxysole group By hydrolyzing the compound of formula (IA) in the presence of an acid or a base, a carboxylic acid compound in which R 3 is a carboxysole group can be obtained. Decarboxylate the carboxylic acid compound by reacting it in the presence of an acid at room temperature to about 150 ° C for 1 to 24 hours, or decarboxylate by heating at room temperature to about 200 ° C in the presence of a base. By this, compound (I) of the present invention in which R 3 is a hydrogen atom can be obtained.
- the compound of formula (I) is reacted with a halogenating reagent (halogen or N-halogenated succinimide) for 1 to 24 hours at room temperature to 100 ° C or at a temperature at which the solvent is refluxed. , to obtain the present invention
- a halogenating reagent halogen or N-halogenated succinimide
- I ⁇ product R 3 is a halogen atom.
- This reaction can be carried out without solvent or by appropriately selecting a solvent such as dioxane, tetrahydrofuran, ethyl ether, n-hexane, cyclohexane, dichloromethane, and chlorophonolem.
- R 3 is a hydroxymethyl group.
- a halogenating agent such as thionyl chloride
- the reaction is carried out with 1 to 2 equivalents of a reducing agent.
- a compound of the formula (IA) is reacted with ammonia, methyl, ethyl, n-propyl, i-propyl, n-butyl, dimethyl, getyl, di-n-propyl, di-ethyl in the presence of 1 to 2 equivalents of a condensing agent.
- R 3 is a carpa'moyl group or methyl, ethyl, n-propyl, i-propyl, n-butyl, dimethyl, getyl, di-n-propyl, di-
- the compound of the present invention represented by a mono- or di-lower alkylcanolebamoinole group such as i-propyl and di-n-butyl can be obtained.
- Examples of the acid used in this reaction include inorganic acids such as sulfuric acid, hydrochloric acid, and nitric acid, and organic acids such as acetic acid, citric acid, oxalic acid, lactic acid, and butyric acid.
- inorganic acids such as sulfuric acid, hydrochloric acid, and nitric acid
- organic acids such as acetic acid, citric acid, oxalic acid, lactic acid, and butyric acid.
- Bases used in this reaction include lithium hydroxide, potassium heptaoxide, alkaline metal hydroxides such as sodium hydroxide, sodium carbonate, alkaline metal carbonates such as carbonated lithium, and carbonic acid.
- Alkali metal bicarbonates such as sodium hydrogen bicarbonate and sodium bicarbonate
- aluminum hydride metal hydrides such as sodium hydride and hydrogen hydride
- inorganic bases such as metal sodium and sodium amide, or triethylamine
- tree ⁇ And organic bases such as -butylamine, pyridine, ⁇ , and ⁇ ⁇ ⁇ ⁇ -dimethylaminopyridine.
- the reduction may be a method of reducing an ester to an alcohol or a method of de-norogenating an alkyl halide, such as lithium aluminum hydride, sodium borohydride, sodium cyanoborohydride or the like.
- condensing agent used in this reaction examples include dicyclohexylcarbodiimide, water-soluble carbodiimide, carbonated lime, sodium hydroxide, hydroxylated lime, toluene sulfonic acid, and sulfuric acid.
- This reaction is carried out without solvent or with dioxane, tetrahydrofuran, getyl ether, ⁇ -hexane, cyclohexane, dichloromethane, chlorophonolem, benzene, xylene, acetonitrile, ⁇ , ⁇ -dimethylformamide, dimethylsulfoxide, etc. It can be carried out by appropriately selecting a solvent.
- the compound (3) can also be obtained by the production process of (Step G) shown in Reaction Scheme 2> below. ⁇ Reaction process formula 2>
- This reaction can be carried out without solvent or by appropriately selecting a solvent such as dioxane, tetrahydrofuran, geethylether, n-hexane, and cyclohexane.
- a solvent such as dioxane, tetrahydrofuran, geethylether, n-hexane, and cyclohexane.
- the compound (I) of the present invention can also be obtained by the production steps of (Step to (Step J)) shown in Reaction Scheme 3> below.
- 1,4-diketone conjugate (11) can be obtained.
- Bases used in this reaction include lithium metal hydroxides such as lithium hydroxide, potassium hydroxide, and sodium hydroxide, sodium metal carbonates such as sodium carbonate and carbon dioxide, sodium hydrogen carbonate, and hydrogen carbonate.
- Alkali metal hydrogencarbonate such as sodium hydride, sodium hydride, alkaline metal hydride such as hydrogen hydride, metal base, inorganic base such as sodium amide, or triethylamine, tri-n-butylamine Organic salts such as pyridine, N, N-dimethylaminopyridine And the like.
- This reaction is carried out without solvent or dioxane, tetrahydrofuran, getyl ether, n-hexane, cyclohexane, dichloromethane, chlorophosolem, ethyl acetate, benzene, xylene, acetone, acetonitrinole, N, N-dimethinolehonolemamide, It can be carried out by appropriately selecting a solvent such as dimethyl sulfoxide.
- the sulfonate compound (12) is added to the 1,4-diketone compound (11) by adding 1 equivalent to an excess amount of the oxidizing agent and reacting at a temperature of about ice cooling to reflux of the solvent for 1 to 24 hours. ) Can be obtained.
- the oxidation may be a method of oxidizing an alkylthio group to an alkylsulfonyl group, and examples thereof include a method using an oxidizing agent such as aqueous hydrogen peroxide and 3-chloroperbenzoic acid.
- the solvent used in this reaction may be appropriately selected depending on the oxidation method. Generally, dioxane, tetrahydrofuran, getyl ether, n-hexane, cyclohexane, dichloromethane, chlorophonolem, benzene, xylene and the like are used. Used.
- the sulfone compound (1 2) is reacted with 1 to 2 equivalents of the amino compound or ammonium salt represented by 2 at room temperature to 100 ° C. or a temperature at which the solvent is refluxed for 1 to 24 hours. Thereby, the compound (I) of the present invention can be obtained.
- Examples of the amine in this reaction include methylamine, ethylamine, n-propylamine, isopropylamine, n-butylamine, s-butylamine, t-butylamine and the like.
- Examples of the ammonium salt in this reaction include ammonium carbonate and ammonium acetate.
- R 1 , R 2 , R 3 , R ⁇ R 5 and R 6 are the same as above.
- W represents B (0H) 2 or Sn (n-Bu) 3 . ]
- the oxidation may be a method of oxidizing an alkylthio group to an alkylsulfonyl group, and examples thereof include a method using an oxidizing agent such as aqueous hydrogen peroxide and 3-chloroperbenzoic acid.
- the solvent used in this reaction may be appropriately selected depending on the oxidation method. In general, dioxane, tetrahydrofuran, dimethyl ether, n-hexane, cyclohexane, dichloromethane, chloroform, benzene, xylene, etc. Is used.
- the compound (14) is reacted with a bromine equivalent at about ice-cooling to about 100 ° C. for 1 to 24 hours to obtain an ⁇ -bromoketone compound (15).
- This reaction can be carried out without solvent or by appropriately selecting a solvent such as dioxane, tetrahydrofuran, getyl ether, ⁇ -hexane, cyclohexane, dichloromethane, chloroform, benzene, or xylene.
- a solvent such as dioxane, tetrahydrofuran, getyl ether, ⁇ -hexane, cyclohexane, dichloromethane, chloroform, benzene, or xylene.
- the ⁇ -bromoketone compound (15) is added with 1 to 2 equivalents of the compound (16) or a salt thereof in the presence of 1 equivalent to an excess amount of a base at room temperature to about 100 ° C.
- the compound (17) can be obtained by reacting for up to 24 hours.
- Bases used in this reaction include alkaline metal hydroxides such as 7j lithium oxide, potassium hydroxide, and sodium hydroxide; alkaline metal carbonates such as sodium carbonate and carbonated carbonate; sodium hydrogen carbonate; and hydrogen carbonate.
- Alkali metal hydrogencarbonates such as sodium hydride, sodium hydride, alkaline metal hydrides such as hydrogen hydride, inorganic bases such as sodium metal, sodium amide or triethylamine, tri-n-butylamine, Organic salts such as pyridine, N, N-dimethylaminopyridine And the like.
- the salt in the present reaction includes sodium salts, potassium salts and the like.
- a solvent such as dioxane, tetrahydrofuran, getyl ether, n-hexane, cyclohexane, dichloromethane, chlorophonolem, benzene, xylene, N, N-dimethylformamide, dimethyl sulfoxide, etc. You can choose to do it.
- the compound (17) can be obtained by reacting 1 to 2 equivalents of a mino compound or an ammonium salt with the solution at room temperature to 100 or at a temperature at which the solvent is refluxed for 1 to 24 hours.
- Examples of the amine in this reaction include methylamine, ethylamine, n-propylamine, isopropylamine, n-butylamine, s-butylamine, t-butylamine and the like.
- Examples of the ammonium salt in this reaction include ammonium carbonate and ammonium acetate. This reaction is carried out without solvent or dioxane, tetrahydrofuran, getylether, n-hexane, cyclohexane, dichloromethane, chloroform, benzene, xylene, N, N-dimethizolefosolem amide, dimethyl sulfoxide, water Such a solvent can be appropriately selected.
- This reaction is carried out without solvent or dioxane, tetrahydrofuran, geethylether, n-hexane, cyclohexane, dichloromethane, chloroform, benzene, xylene, N, N-dimethylformamide, dimethylsulfoxide, methanol, ethanol
- a solvent such as n-propanol or isopropanol can be appropriately selected.
- This reaction is carried out using dioxane, tetrahydrofuran, getinoleatenole, n-hexane, cyclohexane, dichloromethane, chloroform, benzene, xylene, N, N-dimethylinolenolemamide, dimethyl sulfoxide, methanol, Ethanol, n-prono ,. Nord, Isoprono ,. It can be carried out by appropriately selecting a solvent such as ethanol.
- the catalyst in this reaction include tetrakistriphenylphosphine palladium, bistriphenylphosphine palladium chloride, zinc chloride and the like.
- an inorganic acid such as sulfuric acid, hydrochloric acid or nitric acid
- an organic acid such as acetic acid, citric acid, oxalic acid, lactic acid or butyric acid
- Examples of the base used in this reaction include lithium metal hydroxides such as lithium hydroxide, 7j potassium potassium and sodium hydroxide, aluminum carbonate metal salts such as sodium carbonate and carbon dioxide, Alkali metal bicarbonates such as sodium bicarbonate and hydrogen bicarbonate, sodium hydride, alkaline metal hydrides such as hydrogen hydride, inorganic bases such as sodium metal and sodium amide, or triethylamine And organic bases such as tri-n-butylamine, pyridine, N, N-dimethylaminopyridine and the like.
- lithium metal hydroxides such as lithium hydroxide, 7j potassium potassium and sodium hydroxide
- aluminum carbonate metal salts such as sodium carbonate and carbon dioxide
- Alkali metal bicarbonates such as sodium bicarbonate and hydrogen bicarbonate
- sodium hydride alkaline metal hydrides
- inorganic bases such as sodium metal and sodium amide
- organic bases such as tri-n-butylamine, pyridine, N, N-
- the compound (I) of the present invention can also be synthesized by (Step R) to (Step Y) shown in Reaction Scheme 5> below.
- the compound represented by the formula (22) can be obtained by reacting 1 mol of the compound (21) with about 1 mol of bromine at a temperature of about ice-cooled to about 100 ° C for 1 to 24 hours. .
- This reaction can be performed without solvent or by appropriately selecting a solvent such as dioxane, tetrahydrofuran, ethyl ether, n-hexane, cyclohexane, dichloromethane, chlorophonolem, benzene, or xylene.
- 1 mol of the compound of the formula (22) is mixed with 1 to 2 mol of the compound represented by the formula (23) or a salt thereof in the presence of 1 mol to an excess amount of a base in the presence of 1 mol to room temperature to 100 ° C.
- the compound represented by the formula (24) can be obtained by reacting at about the temperature for 1 to 24 hours.
- Examples of the base in this reaction include lithium metal hydroxides such as lithium hydroxide, potassium hydroxide, sodium hydroxide, etc., alkali metal carbonates such as sodium carbonate and carbonated carbonate, sodium hydrogen carbonate, Alkali metal hydrogencarbonates such as bicarbonate lime, sodium hydrogenated hydride such as sodium hydrogenated hydride, inorganic bases such as sodium metal and sodium amide or triethylamine, tri-n And organic bases such as —butylamine, pyridine, N, N-dimethylaminopyridine and the like.
- the salt in this reaction includes a sodium salt, a potassium salt and the like.
- a solvent such as dioxane, tetrahydrofuran, ethyl ether, n-hexane, cyclohexane, dichloromethane, chlorophonolem, benzene, xylene, N, N-dimethylformamide, dimethyl sulfoxide, etc., is appropriately selected. Can be done.
- equation (2 4) of Compound 1 Amino compound represented mol at 1 ⁇ Saku 2 or ammoxidation two ⁇ unsalted 1-2 moles at room temperature ⁇ 1 0 0 ° C or a temperature enough to refluxing of the solvent
- amines in this reaction include methylamine, ethylamine, n-propylamine, isopropylamine, n-butylamine, s-butylamine, t-butylamine, and the like.
- Examples of the ammonium salt used in this reaction include ammonium carbonate and ammonium acetate.
- This reaction is carried out without solvent or with a solvent such as dioxane, tetrahydrofuran, ethyl ether, n-hexane, cyclohexane, dichloromethane, chloroform, benzene, xylene, N, N-dimethylformamide, dimethylsulfoxide, or water. It can be selected appropriately. (Process U)
- This reaction is carried out without solvent or dioxane, tetrahydrofuran, ethyl ether, n-hexane, cyclohexane, dichloromethane, chlorophonolem, benzene, xylene, N, N-dimethylformamide, dimethylsulfoxide, methanol, ethanol, n —Solvents such as propanol and isopropanol can be appropriately selected.
- This reaction is carried out without solvent or in a solvent such as dioxane, tetrahydrofuran, ethyl ether, n-hexane, cyclohexane, dichloromethane, or chloroform.
- a solvent such as dioxane, tetrahydrofuran, ethyl ether, n-hexane, cyclohexane, dichloromethane, or chloroform.
- the compound of the formula (27) is reacted with 1 to 2 mol of an amino compound or an ammonium salt represented by R 7 R 8 NH at a temperature of about room temperature to 100 ° C. for 1 to 24 hours. Thereby, the compound represented by the formula (28) can be obtained.
- Amines in this reaction include ammonia, methylamine, ethylamine, n-propylamine, isopropylamine, n-butylamine, and s-butylamine.
- Tert-butylamine, dimethylamine getylamine, di-n-propylamine, diisopropylamine, di-n-butylamine, di-s-butylamine, di-t-butylamine and the like.
- Examples of the ammonium salt in this reaction include ammonium carbonate and ammonium acetate.
- a solvent such as dioxane, tetrahydrofuran, ethyl ether, n-hexane, cyclohexane, dichloromethane, chlorophonolem, benzene, xylene, N, N-dimethylformamide, dimethylsulfoxide, or water is used as appropriate. You can choose to do it.
- a compound of formula (28) and a base such as sodium carbonate in an amount of about 1 to 2 moles and about an equimolar amount of a compound represented by formula (29) in the presence of a catalyst are added at room temperature to 100 ° C. or in a solvent.
- the compound represented by the formula (IB) can be obtained by reacting the mixture at a temperature at which the reaction is refluxed for 1 to 24 hours.
- This reaction is carried out using dioxane, tetrahydrofuran, ethyl ether, n-hexane, cyclohexane, dichloromethane, chlorophonolem, benzene, xylene, N, N-dimethylformamide, dimethyl snolefoxide, methanol, ethanol, n-propanol, and isopropanol.
- the reaction can be carried out by appropriately selecting a solvent such as ethyl.
- the catalyst in this reaction include tetrakistriphenylphosphine palladium, bistriphenylphosphine palladium chloride, zinc chloride and the like.
- step F the compound of formula (IB) is treated in the same manner as in step F to obtain the compound of the present invention (I).
- the compound (I) of the present invention can also be synthesized by the following (Step Z) to (Step AA) shown in Reaction Scheme 6>. Reaction scheme 6>
- RR 2 , R 3 , R 4 , R s and R 6 are as defined above.
- W represents B (0H) 2 or Sn (n-Bu) 3 . ]
- Compound (30) can be obtained by treating compound (19) in the same manner as in step F.
- the acid used in this reaction include inorganic acids such as sulfuric acid, hydrochloric acid, and nitric acid, and organic acids such as acetic acid, citric acid, oxalic acid, lactic acid, and butyric acid.
- Examples of the base used in this reaction include alkaline metal hydroxides such as lithium hydroxide, potassium hydroxide, and sodium hydroxide, alkaline metal carbonates such as sodium carbonate and carbon dioxide, and carbonic acid.
- Alkali metal bicarbonates such as sodium hydrogen and hydrogen carbonate, sodium metal hydrides, metal hydrides such as hydrogen hydride, inorganic bases such as sodium metal and sodium amide, and triethylamine, etc.
- Organic bases such as Lee ⁇ -butylamine, pyridine, ⁇ , and ⁇ ⁇ ⁇ ⁇ -dimethylaminopyridine.
- the compound (I) of the present invention can be obtained by reacting the above aqueous solution of a base such as sodium carbonate at room temperature to 10 ° C. or a temperature at which the solvent is refluxed for 1 to 24 hours.
- a base such as sodium carbonate
- This reaction is carried out using dioxane, tetrahydrofuran, geethylether, n-hexane, cyclohexane, dichloromethane, chloroform, benzene, xylene, N, N-dimethylformamide, dimethylsulfoxide, methanol, ethanol, n- Solvents such as propanol and isopropanol can be appropriately selected.
- the catalyst in this reaction include tetrakistriphenylphosphine palladium, bistriphenylphosphine palladium chloride, zinc chloride and the like.
- the compounds of the present invention can be administered orally or parenterally in conventional dosage forms.
- the compound which is an active ingredient of the present invention exhibits strong anti-inflammatory action, antipyretic action, analgesic action, anti-rheumatic action and cell growth inhibitory action based on COX-2 selective inhibitory action, and side effects such as gastrointestinal disorders.
- the compound (I) of the present invention is useful as an anti-inflammatory agent, an antipyretic agent, an analgesic agent, an anti-rheumatic agent and an anti-tumor agent, because of its low safety and high safety.
- Tablets The following components are contained in one tablet.
- Capsule One capsule contains the following components.
- Granules One package contains the following components. ,
- Test Example 1 (Ragendin foot edema inhibition test)
- the force lagenin foot edema inhibition test was performed according to the method of Winter et al. [J. Ph a rm.
- test substance suspended in Tween 80 was orally administered at a dose of 1 lm / 100 g body weight, and only a solvent was similarly administered as a control.
- a 1% carrageenan physiological saline solution was subcutaneously administered to the right hind leg foot and skin at 0 to 1 ml.
- the foot volume was measured, and the edema rate (%) was obtained from Equation 1, and the edema inhibition rate (%) was obtained from Equation 2.
- the dose of the test substance was 1 OmgZkg.
- the compound (I) of the present invention was stronger than the control compounds (a) and (b).
- Equation 1 Has the effect of suppressing the force ragenin foot edema and has an excellent anti-inflammatory effect. Equation 1:
- Edema rate (%) [(paw volume after force lagenin injection-one foot volume before force lagenin foot injection) / foot volume before force lagenin injection)] X 100
- Table 1 shows the results of Test Example 1.
- H-37RA strain 0.5 mgZkg, a liquid paraffin rat was administered to the lower right leg of the SD rat.
- To the control group only 0.05 ml of liquid paraffin was similarly administered.
- individuals on which arthritis had developed were selected and divided into groups so that the limb volumes of both left and right hind limbs and the arthritis score were uniform in each group.
- the test substance was orally administered once a day for 7 days from the day of grouping (negative and positive Only the solvent was administered to the active control group).
- the degree of arthritis was quantitatively evaluated by measuring the foot volume of both hind limbs using a volume meter (Muromachi Kikai) and by scoring the degree of gross arthritis shown in Table 2. The scoring criteria in Table 2 were used to give a perfect score of 15.
- Tables 3 and 4 show the left and right hind limb volumes and Table 5 show the arthritis scores from the start of the administration of the test substance (day 21) to the 27th day.
- the dose of the test substance was 3 mg / kg / kg.
- the compound (I) of the present invention showed a remarkable decrease in the volume of the left and right hind limbs and a decrease in arthritis score, and showed an anti-inflammatory effect equivalent to that of the control compound (indomethacin).
- COX-1 and COX-2 activities are measured as follows. Performed in accordance with the method of Trigna et al. [J. Pharma. Ep. Ther. 271, 1705 (1994)] c
- TXB 2 tracer was added to each of the gels except the blank jewels. Furthermore, the TXB 2 antibody Ueru of Te All except NSB and blank Uweru to cover one plastic film added in 50 mu 1, was reacted at room temperature for 18 hours. After the reaction was completed, the gel was emptied and washed five times with a wash buffer. After adding Elman's agent 2001 to each of the gels, the mixture was covered with a plastic film, and the color was developed in the place for 60 minutes. The absorbance at 405 nm was measured with an Iranmno Reader (NJ-2000, manufactured by Nippon Intermed Co., Ltd.). % BZB based on measurement results. Was calculated, and the sample concentration was determined to be 2000 times from the Hill Plot approximation formula.
- PG II 2- monoclonal monoclonal antibody was added to all the wells except NS II and blank wells at 50 1 each, covered with a plastic film, and reacted at room temperature for 18 hours. After the reaction was completed, the well was emptied and washed five times with a wash buffer. After adding Elman's agent 200 ⁇ 1 to each bottle, the plate was covered with a plastic film and developed in the dark for 60 minutes. The absorbance at 405 nm was measured with I-uno Reader (NJ-2000, manufactured by Nippon Intermed Co., Ltd.). % BZB0 was calculated from the measurement results, and the sample concentration was determined to be 40 times from the Hill Plot approximation formula.
- the antipyretic effect was measured as follows.
- the sensor was inserted into the rectum of the rat, and the body temperature one hour later was taken as the basal body temperature.
- the heating body temperature was measured 18 hours later.
- Rats with a fever of 0.75 ° C or more from basal body temperature were selected, and the test substance was orally administered. Measurement was performed at hourly intervals for up to 5 hours.
- the dose of the test substance was 1 Omg / kg.
- the antipyretic effect of the compound (I) of the present invention continued until 5 hours after the administration, and showed the same antipyretic effect as that of the control compound (c).
- Test example 5 analgesic effect test
- the analgesic effect test was performed according to the method of Randall et al. [Arch int. Pharaacodyn. Ther.
- the test substance was orally administered immediately after the pain threshold of the right and left hind limbs was measured 2 hours after the induction of inflammation. Three hours later, the pain threshold of the left and right hind limbs was measured.
- the pain threshold rise rate (%) was calculated by Equation 3.
- the pain threshold fluctuation rate was calculated by Equation 4.
- the dose of the test substance was SnigZkg.
- Pain threshold increase rate (%) [(pain threshold 3 hours after drug administration-pain threshold 2 hours after yeast administration) / (pain threshold before yeast administration-pain threshold 2 hours after yeast administration)] X 100 Equation 4:
- Pain threshold fluctuation rate (%) [1— (pain threshold 3 hours after drug administration Z pain threshold 2 hours after yeast administration)] X 100
- the compound of the present invention (I) showed a higher rate of increase in the pain threshold for inflamed paws as compared to the control compound (c), and the non-inflamed paws showed a similar increase in the threshold as the control compound (c). It showed that it did not affect fluctuations, and that it has excellent analgesic action.
- Table 8 shows the results of Test Example 5.
- Pain threshold rise rate Pain threshold change rate
- the SD rats were fasted overnight, and then water-free 2 hours before administration of the test substance.
- the rats were sacrificed, the stomach was removed, and 8 ml of 2% formalin was injected into the stomach. After gastric fixation, an incision was made along the greater curvature, and the length of gastric damage was measured under a stereoscopic microscope.
- the dose was 3 OmgZkg for the compound (I) of the present invention and
- the compound (I) of the present invention did not show the occurrence of gastric ulcers observed in the nonsteroidal anti-inflammatory drug, indicating the possibility as an anti-inflammatory drug with few side effects.
- NC I National Cancer Institute of the United States
- Adherent cells such as Ca Co-2 and HepG2 were prepared in 0.5 ⁇ 10 5 cells s_ml in each medium and dispensed into 96-well plates (Costar 3695) in 100 1 wells. 37 ° (:, After adhering the cells were cultured for 24 hours under the conditions of 5% C0 2, the number of cells was measured by XT T method to a day 0 number of cells (C o days).
- control group was replaced with the solvent alone, and the test substance-added group was replaced with a medium containing the test substance prepared at each concentration, and cultured at 37 ° C (5% CO 2 for 72 hours).
- the number of cells was measured by the XTT method, and the number of cells (C 3 dav s) on day 3 was examined.
- the control group received only the solvent, and the test substance administration group contained a medium containing the test substance prepared at each concentration. in 0. 5x l 0 5 cel I sZm adjusted to l, 96 Uweru one pre Ichito (Co star 3695) was dispensed in 100 1 / Ueru to.
- the compounds of Production Examples 1 and 37 exhibited a cell growth inhibitory effect on Ca Co-2 cells, which are colon cancer cells.
- Test Example 7 L (T 3 dys —— ⁇ O days (U 3 days —— ⁇ O d ay s) ⁇ IOO
- Table 10 The results of Test Example 7 are shown in Table 10.
- Test substance-C a C ⁇ 2 (cell carcinoma)
- Test Example 8 Test for induction of apoptosis in CaCo-2 cells
- 0-2 cells were prepared in 10% FBSZDMEM ZNEAA at 1.Ox 10 5 ce 11 s / m 1 and dispensed at 6 ml loop rate at 3 ml 1 Z pellet.
- the control group (0.1% ethanol) and the compound of the present invention (Preparation Example 1) group the medium was replaced with a medium containing a compound prepared in each concentration, 3 7 ° C, 5% under the conditions of C 0 2 7 2 hours culture was harvested peeled off media and adherent cells Bok trypsin.
- the antitumor effect on Sarcoma 180 solid tumor mice was determined by the method of the United States National Cancer Institute (NCI) [Cancer Chemotherapy Reports 3, Vol. 3, page 1 (19778). Year)].
- NCI National Cancer Institute
- the murine sarcoma-derived S arc oma 1 8 0 cells 2 x 1 0 7 ce 1 prepared in 1 SZM 1 with Hank's balanced salt solution as a tumor cell line for transplantation, I CR system 5 weeks old that 0. 2m l
- the mice were administered subcutaneously on the back of the mice (5 ⁇ 10 8 ce 11 sZ mice). There were 10 mice per group.
- the compound of the present invention (Production Example 1, Production Example 37), 5-fluorouracil, and a solvent alone were administered intraperitoneally as controls for 10 consecutive days from the first day.
- the mouse On the 1st day, the mouse was sacrificed, a solid tumor was cut out, and its weight was measured. Table 11 shows the results of Test Example 9. The dose of the test substance was lOmgZkg.
- Test example 10 [Acute toxicity test]
- the compound of the present invention (Preparation Example 1) was administered by suspending it in 1% methylcellulose. The dose was 500, 1,000 and 2000 mgZkg. One week after the administration, general symptoms and survival of rats were observed. All groups showed post-dose sedation, but recovered 1 hour later. No deaths were observed, and the body weight increased steadily even after one week of observation, and no abnormalities were observed in general symptoms. From this, it was shown that the compound of the present invention was a highly safe compound.
- Test example 1 [Subacute toxicity test]
- the subacute toxicity test was performed as follows. Six male and female SD rats were used as one group.
- the compound of the present invention (Production Example 1) was suspended in an aqueous solution of 0.5% methylcellulose and administered once a day for 14 days using a disposable gastric tube for rat (manufactured by Fuchigami Kikai).
- the dose of the test substance was 10 OmgZkg. During the treatment period, no change in general condition was observed, and there was no effect on weight gain. This indicates that the compound of the present invention is a highly safe compound.
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP98961615A EP1048649A4 (en) | 1997-12-26 | 1998-12-25 | 5-ARYLPYRROL DERIVATIVES |
US09/582,411 US6294568B1 (en) | 1997-12-26 | 1998-12-25 | 5-arylpyrrole derivatives |
AU16913/99A AU1691399A (en) | 1997-12-26 | 1998-12-25 | 5-arylpyrrole derivatives |
CA002316953A CA2316953A1 (en) | 1997-12-26 | 1998-12-25 | 5-arylpyrrole derivatives |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP9/359171 | 1997-12-26 | ||
JP35917197 | 1997-12-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999033796A1 true WO1999033796A1 (fr) | 1999-07-08 |
Family
ID=18463114
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1998/005972 WO1999033796A1 (fr) | 1997-12-26 | 1998-12-25 | Derives de 5-arylpyrrole |
Country Status (5)
Country | Link |
---|---|
US (1) | US6294568B1 (ja) |
EP (1) | EP1048649A4 (ja) |
AU (1) | AU1691399A (ja) |
CA (1) | CA2316953A1 (ja) |
WO (1) | WO1999033796A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8541471B2 (en) | 2003-05-07 | 2013-09-24 | Osteologix A/S | Water-soluble strontium salts for use in treatment of cartilage and/or bone conditions |
WO2022195579A1 (en) | 2021-03-15 | 2022-09-22 | Saul Yedgar | Hyaluronic acid-conjugated dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (nsaids) for treating or alleviating inflammatory diseases |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1406903B1 (de) * | 2001-07-05 | 2007-02-14 | Basf Aktiengesellschaft | Fungizide triazolopyrimidine, verfahren zu ihrer herstellung und ihre verwendung zur bekämpfung von schadpilzen sowie sie enthaltende mittel |
EP2026615B1 (en) | 2007-07-30 | 2014-10-29 | Ricoh Company, Ltd. | Information processing apparatus, information processing system, and program product |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4477463A (en) * | 1982-05-10 | 1984-10-16 | E. I. Du Pont De Nemours And Company | Antiinflammatory and/or analgesic 1-alkyl-4,5-diaryl-2-fluoroalkyl-1H-pyrroles |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL7012852A (ja) | 1969-09-02 | 1971-03-04 | ||
US4267184A (en) | 1979-02-08 | 1981-05-12 | E. I. Du Pont De Nemours And Company | Antiinflammatory 4,5-diaryl-2-(substituted-thio)pyrroles and their corresponding sulfoxides and sulfones |
DK350280A (da) | 1979-08-27 | 1981-02-28 | Du Pont | Fremgangsmaade til fremstilling af 4,5-diaryl-alfapolyfluoralkyl-1h-pyrrol-2-methanoler og 1-(4,5-diaryl-1h-pyrrol-2-yl)-polyfluoralkanoner |
US4335136A (en) | 1980-04-18 | 1982-06-15 | E. I. Du Pont De Nemours And Company | Anti-inflammatory 4,5-diaryl-α-(polyfluoroalkyl)-1H-pyrrole-2-methanamines |
US4267190A (en) | 1980-04-18 | 1981-05-12 | E. I. Du Pont De Nemours And Company | Antiinflammatory 4,5-diaryl-α,α-bis(polyfluoromethyl)-1H-pyrrole-2-methanethiols |
US4318917A (en) | 1981-01-21 | 1982-03-09 | E. I. Du Pont De Nemours And Company | Antiinflammatory 2,3-diaryl-5-[2,2,2-trifluoro-1-(trifluoromethyl]ethyl-1H-pyrroles |
US4652582A (en) | 1985-01-09 | 1987-03-24 | E. I. Du Pont De Nemours And Company | Antiinflammatory-2-halo-4,5-diarylpyrroles |
-
1998
- 1998-12-25 US US09/582,411 patent/US6294568B1/en not_active Expired - Fee Related
- 1998-12-25 AU AU16913/99A patent/AU1691399A/en not_active Abandoned
- 1998-12-25 WO PCT/JP1998/005972 patent/WO1999033796A1/ja not_active Application Discontinuation
- 1998-12-25 EP EP98961615A patent/EP1048649A4/en not_active Ceased
- 1998-12-25 CA CA002316953A patent/CA2316953A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4477463A (en) * | 1982-05-10 | 1984-10-16 | E. I. Du Pont De Nemours And Company | Antiinflammatory and/or analgesic 1-alkyl-4,5-diaryl-2-fluoroalkyl-1H-pyrroles |
Non-Patent Citations (3)
Title |
---|
See also references of EP1048649A4 * |
WILKERSON W. W., ET AL.: "ANTIINFLAMMATORY 4,5-DIARYLPYRROLES. 2. ACTIVITY AS A FUNCTION OF CYCLOOXYGENASE-2 INHIBITION.", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 38., no. 20., 1 January 1995 (1995-01-01), US, pages 3895 - 3901., XP002920001, ISSN: 0022-2623, DOI: 10.1021/jm00020a002 * |
WILKERSON W. W., ET AL.: "ANTIINFLAMMATORY 4,5-DIARYLPYRROLES: SYNTHESIS AND QSAR.", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 37., no. 07., 1 January 1994 (1994-01-01), US, pages 988 - 998., XP002920002, ISSN: 0022-2623, DOI: 10.1021/jm00033a017 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8541471B2 (en) | 2003-05-07 | 2013-09-24 | Osteologix A/S | Water-soluble strontium salts for use in treatment of cartilage and/or bone conditions |
WO2022195579A1 (en) | 2021-03-15 | 2022-09-22 | Saul Yedgar | Hyaluronic acid-conjugated dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (nsaids) for treating or alleviating inflammatory diseases |
Also Published As
Publication number | Publication date |
---|---|
EP1048649A4 (en) | 2001-03-21 |
CA2316953A1 (en) | 1999-07-08 |
AU1691399A (en) | 1999-07-19 |
US6294568B1 (en) | 2001-09-25 |
EP1048649A1 (en) | 2000-11-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2423793T3 (es) | Compuestos agonistas de PPAR, preparación y usos para el tratamiento de la diabetes y/o dislipidemias | |
KR100796851B1 (ko) | 사이클록시게나아제-2의 억제제로서 1-(4-설파밀아릴)-3-치환형-5-아릴-2-피라졸린 | |
EP1246809B1 (en) | 5-aryl-1h-1,2,4-triazole compounds as inhibitors of cyclooxygenase-2 and pharmaceutical compositions containing them | |
CN102149384B (zh) | 作为ep4受体拮抗剂的杂环酰胺衍生物 | |
MXPA06001739A (es) | Derivado de acido arilalcanoico substituido y uso del mismo. | |
HU227830B1 (hu) | 1,2-Difenil-pirrol-származékok, alkalmazásuk és ilyeneket tartalmazó gyógyászati készítmények | |
KR19990063989A (ko) | 염증 치료용의 1,3,5-삼치환된 피라졸 화합물 | |
TW520365B (en) | Novel 3,4-diarylthiazolin-2-one or -2-thione derivatives, their methods of preparation and their uses in therapeutics | |
WO1999033796A1 (fr) | Derives de 5-arylpyrrole | |
MXPA01003069A (es) | Derivados de 2-fenilpiran-4-cetona. | |
WO2008006626A1 (en) | Triphenyl modified 5-membered heterocycles and their use as anticancer and antiinflammatory agents | |
JP2007522181A (ja) | シクロオキシゲナーゼ−1及びシクロオキシゲナーゼ−2阻害剤としての置換アゼチジン化合物、ならびにそれらの調製、および薬剤としての使用 | |
Srilakshmi et al. | Design, In Silico Studies, Synthesis, Characterization, and Biological Activities of Novel Substituted Oxazole Derivatives | |
CA2403732A1 (en) | Novel imidazole derivatives with anti-inflammatory activity | |
JPH0753730B2 (ja) | イミダゾピラゾール誘導体 | |
IE883598L (en) | Acyl derivatives of hydroxy pyrimidines | |
JP3015702B2 (ja) | イミダゾール誘導体及びそれらの薬剤として許容される酸付加塩及びその製造法並びにそれらを有効成分とする抗潰瘍剤 | |
US7230010B2 (en) | 1,2,4-triazole derivative, method for preparing the same, and pharmaceutical composition containing the same | |
EP2459532B1 (en) | Antitumor 1,2-diphenylpyrrole compounds and their preparation process | |
JP4759207B2 (ja) | 1−(ベンゾチアゾール−2−イル)ピラゾール誘導体およびそれを含有するcox−2阻害剤 | |
BG107101A (bg) | 2-фенилпиран-4-онови производни | |
KR20020093952A (ko) | 항염증 작용을 갖는 신규한 헤테로시클릭 화합물 | |
Parmar et al. | Novel thiophene derivatives as Anti-inflammatory agents | |
EP1515952A2 (en) | Pyrazole-3-one derivative, method for preparing the same, and pharmaceutical composition containing the same | |
JPH02129181A (ja) | 1−アリール−4−(1h−イミダゾール−1−イル)フタラジン誘導体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1998961615 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09582411 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2316953 Country of ref document: CA Ref country code: CA Ref document number: 2316953 Kind code of ref document: A Format of ref document f/p: F |
|
WWP | Wipo information: published in national office |
Ref document number: 1998961615 Country of ref document: EP |
|
WWR | Wipo information: refused in national office |
Ref document number: 1998961615 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998961615 Country of ref document: EP |